Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

